Email this article CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER
- Authors: Gridneva Y.V.1, Matveev V.B.1, Bukharkin B.V.1, Kupchan D.Z.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: Vol 6, No 4 (2010)
- Pages: 54-60
- Section: PROSTATE CANCER
- Published: 30.12.2010
- URL: https://oncourology.abvpress.ru/oncur/article/view/356
- DOI: https://doi.org/10.17650/1726-9776-2010-6-4-54-60
- ID: 356
Cite item
Full Text
Abstract
Second-line hormonal therapy, chemo- and glucocorticosteroid therapy, treatment with aminog-lutetimides, ketoconazole, suramin, target agents, and vaccines may be singled out among the basic treatments for hormone refractory prostate cancer (HRPC). There is a search for a new ef-fective therapy for HRPC, which is associated with the development of new regimens based on docetaxel in combination with target therapy and new classes of antitumor drugs, which shows promise of improving the results of treatment for this disease.
About the authors
Ya. V. Gridneva
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: gridnevyana@mail.ru
Russian Federation
V. B. Matveev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: gridnevyana@mail.ru
Russian Federation
B. V. Bukharkin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: gridnevyana@mail.ru
Russian Federation
D. Z. Kupchan
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: gridnevyana@mail.ru
Russian Federation
References
Supplementary files
